- Home
- GROW vs IGC Comparison
GROW vs IGC Comparison
Compare GROW & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GROW
- IGC
- Stock Information
- Founded
- GROW 1968
- IGC 2005
- Country
- GROW United States
- IGC United States
- Employees
- GROW N/A
- IGC N/A
- Industry
- GROW Investment Managers
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- GROW Finance
- IGC Health Care
- Exchange
- GROW Nasdaq
- IGC Nasdaq
- Market Cap
- GROW 34.9M
- IGC 23.8M
- IPO Year
- GROW N/A
- IGC N/A
- Fundamental
- Price
- GROW $2.43
- IGC $0.40
- Analyst Decision
- GROW
- IGC Strong Buy
- Analyst Count
- GROW 0
- IGC 2
- Target Price
- GROW N/A
- IGC $3.63
- AVG Volume (30 Days)
- GROW 40.5K
- IGC 713.9K
- Earning Date
- GROW 12-12-2024
- IGC 11-11-2024
- Dividend Yield
- GROW 3.67%
- IGC N/A
- EPS Growth
- GROW N/A
- IGC N/A
- EPS
- GROW 0.09
- IGC N/A
- Revenue
- GROW $10,984,000.00
- IGC $1,062,000.00
- Revenue This Year
- GROW N/A
- IGC N/A
- Revenue Next Year
- GROW N/A
- IGC $13.57
- P/E Ratio
- GROW $27.33
- IGC N/A
- Revenue Growth
- GROW N/A
- IGC N/A
- 52 Week Low
- GROW $2.38
- IGC $0.25
- 52 Week High
- GROW $3.11
- IGC $0.91
- Technical
- Relative Strength Index (RSI)
- GROW 35.11
- IGC 57.09
- Support Level
- GROW $2.38
- IGC $0.35
- Resistance Level
- GROW $2.52
- IGC $0.41
- Average True Range (ATR)
- GROW 0.06
- IGC 0.02
- MACD
- GROW -0.00
- IGC 0.00
- Stochastic Oscillator
- GROW 25.00
- IGC 74.00
About GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.